OBJECTIVES: @entity3284 -associated @entity397 are a recognised complication, but other severe collagen-associated adverse events may also be possible. Our objectives were to confirm the association of @entity2887 and @entity397 , to clarify the potential association of @entity2887 and @entity1713 , and to test for a potentially lethal association between @entity2887 and @entity449 . SETTING: Population-based longitudinal cohort study in Ontario, Canada. @entity1 : Older adults turning 65   years between April 1 1997 and March 31 2012 were followed until primary outcome, @entity204 , or end of follow-up (March 31 2014). @entity3284 prescriptions were measured as a time-varying covariate, with @entity1 considered at risk during and for 30   days following a treatment course. PRIMARY OUTCOME MEASURES: Severe collagen-associated adverse events defined as @entity397 , @entity1713 and @entity449 diagnosed in hospital and emergency departments. RESULTS: Among the 1   744   360 eligible @entity1 , 657   950 (38%) received at least one @entity3284 during follow-up, amounting to 22   380   515 days of treatment. The @entity1 experienced 37   338 (2.1%) @entity397 , 3246 (0.2%) @entity1713 , and 18   391 (1.1%) @entity449 . Severe collagen-associated adverse events were more common during @entity3284 treatment than control periods, including @entity397 (0.82 vs 0.26/100- @entity1 years, p<0.001), @entity1713 (0.03 vs 0.02/100- @entity1 -years, p=0.003) and @entity449 (0.35 vs 0.13/100- @entity1 -years, p<0.001). Current @entity2887 were associated with an increased hazard of @entity397 (HR 3.13, 95% CI 2.98 to 3.28; adjusted HR 2.40, 95% CI 2.24 to 2.57) and an increased hazard of @entity449 (HR 2.72, 95% CI 2.53 to 2.93; adjusted HR2.24, 95% CI 2.02 to 2.49) that were substantially greater in magnitude than the association of these outcomes with @entity115 . The hazard of @entity1713 was marginal (HR 1.28, 95% CI 0.99 to 1.65; adjusted HR 1.47, 95% CI 1.08 to 2.00) and not greater in magnitude than that observed with @entity115 . CONCLUSIONS: @entity2887 are associated with subsequent @entity397 and may also contribute to @entity449 .

XXXX and collagen associated severe adverse events: a longitudinal cohort study.

@entity1 :: ('9606', 'Species') :: ['patients', 'person', 'PARTICIPANTS'] @entity449 :: ('MESH:D001014', 'Disease') :: ['aortic aneurysms'] @entity115 :: ('MESH:D000658', 'Chemical') :: ['amoxicillin'] @entity3284 :: ('D024841', 'Chemical') :: ['Fluoroquinolone', 'fluoroquinolone'] @entity1713 :: ('MESH:D012163', 'Disease') :: ['retinal detachments', 'retinal detachment'] @entity2887 :: ('MESH:D024841', 'Chemical') :: ['Fluoroquinolones', 'fluoroquinolones'] @entity397 :: ('MESH:D012421', 'Disease') :: ['tendon rupture', 'tendon ruptures'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death']
@entity2887 :: (MESH:D024841,Chemical) :: ['Fluoroquinolones']
